AbCellera Biologics Inc.(ABCL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,534 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ABCL
Events flagged as statistical outliers against ABCL's own multi-year baseline — not fixed dollar thresholds.
- Record insider buy2026-08-24
Largest insider buy on record for ABCL: Hayden Michael R (Director) purchased $570,442
View source filing → - Insider cluster2026-08-24
3 insiders bought $1,545,680 of ABCL in 30 days — 5.7σ above this company's 2-year norm
View source filing → - Insider cluster2026-08-18
3 insiders bought $975,237 of ABCL in 30 days — 5.7σ above this company's 2-year norm
View source filing → - Insider cluster2026-08-14
2 insiders bought $864,937 of ABCL in 30 days — 3.7σ above this company's 2-year norm
View source filing → - Record insider buy2026-08-12
Largest insider buy on record for ABCL: Hayden Michael R (Director) purchased $481,033
View source filing →
ABCL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for AbCellera Biologics Inc. (ABCL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABCL at 29.3/100 on a 32-signal composite quality model, placing it at rank #2,534 of 2,961 stocks — the bottom half of the AI-ranked universe. ABCL scores in the top quartile across revenue growth (91.5). Areas of concern include free cash flow (4.8) and profitability (4.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AbCellera Biologics Inc. reports quarterly revenue of $4.0M, net income of $-55.4M, free cash flow of $23.8M. Top institutional holders of ABCL by reported 13-F value include BAKER BROS. ADVISORS, Capital World Investors, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. ABCL trades on the Nasdaq exchange and files with the SEC under CIK 1703057. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABCL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AbCellera Biologics Inc. directly from SEC EDGAR. AbCellera Biologics Inc.'s 13F Pro composite quality score has ranged between 10 and 78 since 2022, currently 29.3 — a declining long-term trajectory across 65 quarterly and live scoring snapshots.
Revenue
Q2 2026
$4.0M
Net Income
Q2 2026
$-55.4M
Free Cash Flow
Q2 2026
$23.8M
ROIC
Q2 2026
-28.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+160.6% YoYNet Income
+10.1% YoYOperating Income
+31.0% YoYEPS (Diluted)
+10.9% YoYTotal Assets
-0.3% YoYTotal Debt
Op. Cash Flow
-20.9% YoYFree Cash Flow
+6.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $75.1M +160.6% | $28.8M -24.2% | $38.0M -92.2% | $485.4M +29.4% | $375.2M +60.9% | $233.2M |
| Net Income | $-146.4M +10.1% | $-162.9M -11.2% | $-146.4M -192.4% | $158.5M +3.3% | $153.5M +29.1% | $118.9M |
| Operating Income | $-217.1M +31.0% | $-314.8M -32.7% | $-237.2M -209.6% | $216.5M +5.9% | $204.4M +31.0% | $156.0M |
| EPS (Diluted) | $-0.49 +10.9% | $-0.55 -7.8% | $-0.51 -202.0% | $0.50 +4.2% | $0.48 +6.7% | $0.45 |
| Total Assets | $1.36B -0.3% | $1.36B -8.6% | $1.49B -3.4% | $1.54B +16.9% | $1.32B +31.1% | $1.01B |
| Total Debt | — | — | — | — | — | $190.0K |
| Operating Cash Flow | $-131.3M -20.9% | $-108.6M -147.4% | $-43.9M -115.8% | $277.4M +13.4% | $244.6M +977.9% | $22.7M |
| Free Cash Flow | $-174.1M +6.9% | $-187.0M -54.7% | $-120.8M -158.5% | $206.7M +11.1% | $186.1M +1329.9% | $13.0M |
Get alerted when ABCL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AbCellera Biologics Inc. including:
Top Institutional Holders of ABCL
BAKER BROS. ADVISORS LP
$259.1M33,012,138 shCapital World Investors
$106.7M13,588,349 shTWO SIGMA INVESTMENTS, LP
$81.9M10,437,431 shTD Waterhouse Canada Inc.
$72.6M9,568,149 shBANK OF AMERICA CORP /DE/
$48.2M6,141,539 shUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$33.9M4,317,206 shArrowMark Colorado Holdings LLC
$32.2M4,105,095 shBlackRock, Inc.
$29.9M3,805,309 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$22.7M2,886,000 shDRIEHAUS CAPITAL MANAGEMENT LLC
$22.5M2,864,729 sh
| Fund | Value | Shares |
|---|---|---|
| BAKER BROS. ADVISORS LP | $259.1M | 33,012,138 |
| Capital World Investors | $106.7M | 13,588,349 |
| TWO SIGMA INVESTMENTS, LP | $81.9M | 10,437,431 |
| TD Waterhouse Canada Inc. | $72.6M | 9,568,149 |
| BANK OF AMERICA CORP /DE/ | $48.2M | 6,141,539 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME | $33.9M | 4,317,206 |
| ArrowMark Colorado Holdings LLC | $32.2M | 4,105,095 |
| BlackRock, Inc. | $29.9M | 3,805,309 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22.7M | 2,886,000 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $22.5M | 2,864,729 |
Companies Similar to ABCL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
REGENXBIO Inc.
AGIOS PHARMACEUTICALS, INC.
BICYCLE THERAPEUTICS PLC
Kymera Therapeutics, Inc.
Crinetics Pharmaceuticals, Inc.
Coherus Oncology, Inc.
ImmunityBio, Inc.
Invivyd, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ABCL on your watchlist
Track score changes the day AbCellera Biologics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ABCL a good stock to buy?
13F Pro's AI-powered analysis of AbCellera Biologics Inc. (ABCL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABCL are available on the ABCL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ABCL is classified as a mid company.
Which hedge funds own ABCL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABCL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AbCellera Biologics Inc.'s investment landscape.